Fremanezumab in Children and Adolescents with Episodic Migraine
Cincinnati Children's Hospital Medical Center · University of Cincinnati · +10 more institutions
Abstract
Fremanezumab, a humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, is approved for the prevention of migraine in adults. Evidence from randomized, controlled trials in children and adolescents is needed.
We randomly assigned participants 6 to 17 years of age with a diagnosis of episodic migraine (defined as migraine for ≥6 months and a history of ≤14 headache days per month) to receive monthly subcutaneous injections of fremanezumab (120 mg for participants with a body weight of
Citation impact
- FWCI
- 142.98
- Percentile
- 100%
- References
- 29
Authors
11- ADAndrew D. HersheyCorresponding
Cincinnati Children's Hospital Medical Center, University of Cincinnati
- CLChristina L. Szperka
Children's Hospital of Philadelphia, University of Pennsylvania
- PBPiero Barbanti
Vita-Salute San Raffaele University, San Raffaele University of Rome, IRCCS Ospedale San Raffaele
- PPPatricia Pozo-Rosich
Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca
- PBPetra Bittigau
Charité - Universitätsmedizin Berlin
Topics & keywords
- Migraine
- Adverse effect
- Migraine Disorders
- Event (particle physics)
- Headaches
- Adverse drug event
- Good health and well-being